[Form 3] Radiopharm Theranostics Ltd Initial Statement of Beneficial Ownership
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Radiopharm Theranostics Ltd Managing Director and CEO Riccardo Canevari has filed a Form 3 reporting his initial ownership position. The filing shows direct ownership of 22,679,986 Ordinary Shares, along with multiple option awards over additional Ordinary Shares at exercise prices ranging from $0.025 to $0.60 per share and expirations between 2026 and 2030.
Footnotes state that significant blocks of options granted in 2023, 2024 and 2025 will vest in stages on July 1 of 2026, 2027 and 2028, provided Mr. Canevari remains a Director on those dates.
Positive
- None.
Negative
- None.
Insider Trade Summary
15 transactions reported
Mixed
15 txns
Insider
Canevari Riccardo
Role
Managing Director and CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Option (right to buy) — 1,225,352 shares (Direct);
Ordinary Shares — 22,679,986 shares (Direct)
Footnotes (1)
- Granted on December 01, 2023 and will vest on July 1, 2026 provided Mr. Canevari is still a Director on such dates. Granted on December 16, 2024. 18,416,762 options will vest on July 1, 2026 and 18,416,762 options will vest on July 1, 2027 provided Mr. Canevari is still a Director on such dates. Granted on December 12, 2025. 24,776,855 options will vest on July 1, 2026, 24,776,855 options will vest on July 1, 2027 and 24,784,290 options will vest on July 1, 2028 provided Mr. Canevari is still a Director on such dates.
FAQ
What does the Radiopharm (RADX) Form 3 filing by Riccardo Canevari show?
The Form 3 shows CEO Riccardo Canevari’s initial ownership in Radiopharm, including 22,679,986 Ordinary Shares and multiple option awards. These options cover tens of millions of shares at exercise prices between $0.025 and $0.60, with expirations extending to 2030.
What option grants are reported for Radiopharm (RADX) CEO Riccardo Canevari?
The filing reports several option grants over Ordinary Shares with exercise prices from $0.025 to $0.60 per share and expirations between 2026 and 2030. These options, if exercised, would allow Mr. Canevari to acquire substantial additional equity in Radiopharm.
When do Riccardo Canevari’s Radiopharm (RADX) options vest according to the Form 3?
Footnotes state options granted in 2023, 2024 and 2025 will vest in tranches on July 1, 2026, July 1, 2027 and July 1, 2028. Vesting is conditional on Mr. Canevari continuing to serve as a Director on those specific vesting dates.
What are the lowest and highest exercise prices of Radiopharm (RADX) options held by Riccardo Canevari?
The options reported have exercise prices ranging from $0.025 per Ordinary Share at the low end to $0.60 per share at the high end. Each option series also has its own expiration date, running from 2026 through 2030.